Supplement research

Creatine research, and the GLP-1 evidence that does not exist

Two separate research literatures are often spoken about as if they were one. Creatine has been studied for decades in athletes, untrained adults, and older adults doing resistance training. GLP-1 receptor agonists have been studied for weight reduction in people with overweight and obesity. No published randomised trial has combined them. Everything said about the pairing is inference, and this page tries to keep the inference visible rather than hiding it inside confident-sounding prose.

What the creatine trials actually measured

Creatine monohydrate is among the most heavily studied ergogenic aids in the sport-nutrition literature. The International Society of Sports Nutrition position stand summarises several decades of controlled trials and concludes that creatine is the most effective supplement studied for increasing high-intensity exercise capacity and training-related lean mass in the populations examined.¹

An earlier meta-analysis pooled controlled trials of creatine and reported small average advantages over placebo in body composition and in performance on short, high-intensity tasks. The word to hold onto is average. These are group means across trials of healthy participants who were, in nearly all cases, training. They describe what happened in those samples; they do not describe what will happen in a different population under different conditions.²

The published protocols commonly used a short loading phase followed by a lower maintenance phase, and some used maintenance only. That is a description of trial methodology, not a recommendation. This site does not state intake amounts, and any decision about taking a supplement — particularly alongside a prescribed medication — belongs with a qualified healthcare professional who knows your history.¹⁵

The older-adult resistance-training evidence

The most directly relevant body of work, for anyone worried about losing lean tissue, is the older-adult literature. A meta-analysis of trials in older adults combining creatine with a resistance-training programme reported greater increases in lean tissue mass and in muscular strength than resistance training with placebo.³

Two constraints matter. First, the comparison was creatine plus training against placebo plus training — training was present in both arms, and the trials do not speak to creatine without it. Second, the participants were older adults, not adults in an active pharmacological weight-reduction programme with a substantial energy deficit. Applying the pooled estimate to a person losing weight on a GLP-1 receptor agonist is an extrapolation across populations, and it should be labelled as one.³

The measurement problem: water is not muscle

This is the point that matters most on a site about tracking body composition. Creatine supplementation increases total body water. A controlled study measuring fluid compartments reported an increase in total body water without a change in the proportional distribution between intracellular and extracellular space.⁴

DXA and bioelectrical impedance do not measure contractile tissue directly. DXA resolves body mass into fat, bone mineral, and a residual lean soft-tissue compartment — and water sits inside that compartment. BIA infers composition from the electrical properties of body fluid, so it is even more sensitive to hydration state. If a lean-mass reading rises in the weeks after someone starts creatine, the honest interpretation is that the number rose. Whether it rose because of added water, added tissue, or both cannot be separated by the scan.⁴⁵

The practical consequence is that a before-and-after lean-mass comparison spanning the start of creatine use is not a clean comparison. Neither is the reverse: stopping creatine can lower the reading without any tissue being lost. Noting the supplement start and stop dates alongside each scan is the only way to keep the trend interpretable later.⁵

The regulatory position and the common misconceptions

In the European Union, a health-claim opinion evaluated creatine specifically in combination with resistance training for improvement in muscle strength, under the Article 13(5) route of Regulation (EC) No 1924/2006. The framing is worth noting: the claim assessed was about a combination. The regulatory assessment did not treat creatine as something that improves strength in the absence of training.⁶

A separate review addressed the questions and misconceptions that recur in the published and popular literature — including claims about kidney damage in healthy people, dehydration and cramping, hair loss, and the idea that gains are purely water. The authors argue that the balance of published evidence does not support the stronger versions of these claims in the healthy populations studied, while noting that clinical populations and specific medical conditions were not the subject of those trials.⁵

That last caveat is the relevant one here. A safety record established in healthy trained and older adults is not the same thing as a safety record in someone with reduced food and fluid intake under an appetite-suppressing medication.¹⁵

The central gap: creatine has never been trialled with a GLP-1

The large obesity trials of GLP-1 and dual receptor agonists — STEP 1 for semaglutide and SURMOUNT-1 for tirzepatide — reported substantial reductions in body weight, with body-composition substudies in subsets of participants. Neither trial was designed to test a supplement. Supplement use was not an intervention, was not randomised, and was not reported as a controlled variable, so the published results cannot tell us anything about how creatine behaves in that setting.⁷⁸

So the pairing rests entirely on inference across two literatures with non-overlapping populations: creatine trials in training adults without pharmacological weight reduction, and GLP-1 trials in people losing weight without a supplement protocol. Inference across that gap can be reasonable. It is not evidence, and it should not be presented as evidence.¹⁷⁸

Three specific unknowns follow, and none of them has been directly studied:

• Hydration status. Creatine increases total body water, while appetite suppression during GLP-1 treatment can reduce both food and fluid intake. How those two effects interact has not been measured.
• Gastrointestinal tolerability. Nausea, vomiting, and diarrhoea were among the most frequently reported adverse events in the GLP-1 obesity trials, and gastrointestinal discomfort is also among the complaints discussed in the creatine literature. Whether the two overlap, compound, or are unrelated is untested.
• Baseline supplement use. The obesity trials did not record or control creatine intake, so there is no subgroup, however imperfect, to look at retrospectively.⁴⁵⁷⁸

See what the semaglutide trials reported about body composition

Questions people ask

Nothing on this page is a recommendation to take or avoid a supplement, and no intake amount is given anywhere in it. It is a description of what has been published, and a description of what has not.